1naresh2naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) [1954651e-dff7-4710-bb0a-a2e88edb6d79] => Array ( [runtime-id] => 1954651e-dff7-4710-bb0a-a2e88edb6d79 [type] => toll-free-key [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [99ad9c8c-90cf-46bd-8252-4170b8d1dfaf] => Array ( [runtime-id] => 99ad9c8c-90cf-46bd-8252-4170b8d1dfaf [type] => toll-free-key ) ) [credentials] => Array ( [method] => toll-free-key [value] => tf_ipsecsha;3221358099a564a9fd1c91ca1c6b5a56902a9aee ) ) ) 1naresh2nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) [1954651e-dff7-4710-bb0a-a2e88edb6d79] => Array ( [runtime-id] => 1954651e-dff7-4710-bb0a-a2e88edb6d79 [type] => toll-free-key [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [99ad9c8c-90cf-46bd-8252-4170b8d1dfaf] => Array ( [runtime-id] => 99ad9c8c-90cf-46bd-8252-4170b8d1dfaf [type] => toll-free-key ) ) [credentials] => Array ( [method] => toll-free-key [value] => tf_ipsecsha;3221358099a564a9fd1c91ca1c6b5a56902a9aee ) ) )TABLE 2:Summary of sequential examination findings and chemotherapy protocol
Date Chemotherapy Examination Findings November 26, 1999 MRI (Fig 1) Minimum high intensity in the basal ganglia and thalamus on T2-weighted, dural/arachnoid enhancement with Gd-DTPA November 30, 1999 CHOP I-123 IMP (Fig 2A) Very high rCBF throughout the brain before the first half-dose CHOP December 20, 1999 I-123 IMP (Fig 2B) rCBF decreased to a level within normal range after the two half-dose CHOP February 5, 2001 THE-COP February 6, 2001 CT (Fig 3) Increased vascular densities in the left cerebral hemisphere, 6 hours after the onset of right hemiparesis February 9, 2001 I-123 IMP (Fig 2C) High rCBF in the left cerebral hemisphere and the right cerebellum, 2 hours after the recovery from right hemiparesis February 19–22, 2001 EPOCH February 20, 2001 I-123 IMP (Fig 2D) Relatively high rCBF at similar degree in both the right and the left cerebral hemispheres.